VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
AMRNAmarin Corporation plc
$15.91$331M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksAMRNBalance Sheet

Amarin Corporation plc (AMRN) Balance Sheet

30Y historyFree accessUpdated daily

The company's financial position is characterized by a substantial $1.7 billion accumulated deficit and a shrinking asset base, which declined from $831.7 million in 2023Q4 to $645.8 million by 2026Q1.

AMRN Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Aug'98Aug'97Aug'96
Total Current Assets626.02M649.88M595.4M724.98M689.1M878.73M879.23M855M378M153.27M146.33M143.52M145.28M219.4M285.69M118.97M33.11M56.05M16.14M21.73M39.59M36.67M12.99M14.6M47.64M41.62M24.56M12.07M6.3M22.3M20.9M
Cash & Short-Term Investments307.82M302.79M294.22M320.66M309.36M454.13M500.93M644.59M249.23M73.64M98.25M106.96M119.54M191.51M260.24M116.6M31.44M52.26M11.24M18.3M36.8M33.91M10.99M2.1M24.29M30.19M2.02M1.61M800K5.6M4.8M
Cash Only131.06M134.86M121.04M199.25M217.67M219.45M186.96M644.59M249.23M73.64M98.25M106.96M119.54M191.51M260.24M116.6M31.44M52.26M11.24M18.3M36.8M33.91M10.99M2.1M24.29M30.13M2.02M1.61M800K5.6M4.8M
Short-Term Investments176.76M167.93M173.18M121.41M91.69M234.67M313.97M00000000000000000064K00000
Accounts Receivable108.05M126.83M122.28M133.56M130.99M163.65M154.57M116.43M66.52M45.32M19.98M13.83M7.84M3.65M0001.19M674K1.7M1.62M2.08M1.31M1.33M14.52M7.22M4.34M6.9M3.6M7.4M14.8M
Days Sales Outstanding204.39216.68195.23158.84129.5102.4391.8898.89105.9391.3356.0861.7352.8150.49-----84.451.18K1.52K471.9566.1180.9528.02100.77224.47131.4111.15251.26
Inventory183.59M195.91M166.05M258.62M228.73M234.68M188.86M76.77M57.8M30.26M20.51M18.98M13.73M21.21M21.26M0000881K414K002.65M7.73M3.55M2.81M3.41M1.1M1.3M1.4M
Days Inventory Outstanding657.21770.73411.65667.71658.89706524.45291.82386.81245.7217.82248.59244.69649.8717.19K--------81.2393.6960.39221.89418.6108.51169.46127.75
Other Current Assets26.56M24.35M12.85M525K20.02M3.92M3.92M3.91M1.5M600K600K600K1.53M3.03M4.19M2.37M1.67M2.6M4.23M840K42K007.5M0015.05M150K800K8M-100K
Total Non-Current Assets19.75M20.89M89.95M106.7M197.08M189.34M86.79M27.2M7.72M8.33M20.67M29.94M25.83M33.07M25.16M7.41M2.25M145K20.52M20.53M9.23M10.09M10.73M32.78M49.89M49.38M24.04M21.68M10.2M17.9M24M
Property, Plant & Equipment6.01M6.47M7.61M8.42M9.95M9.09M10.07M10.87M63K28K78K243K381K579K811K432K88K128K595K595K282K460K427K1.03M2.39M2.23M1.44M1.63M6.2M9.1M6.3M
Fixed Asset Turnover31.44x33.01x30.05x36.43x37.11x64.19x60.98x39.53x3638.32x6468.00x1667.74x336.44x142.26x45.51x-----12.38x1.77x1.09x2.38x7.14x27.43x2.24x10.97x6.89x1.61x2.67x3.41x
Goodwill013.36M00000000000000000000000000000
Intangible Assets12.73M016.39M19.3M21.78M23.55M13.82M15.26M7.48M8.13M8.77M9.42M10.06M10.71M11.36M00019.92M19.92M8.95M9.63M10.3M31.75M47.5M47.15M22.61M20.06M4M8.7M9.2M
Long-Term Investments00001.27M35M62.47M00-1.74M00200K3.3M3.3M0017K6K000000000000
Other Non-Current Assets1.01M1.05M65.95M78.97M164.08M121.71M432K1.07M174K174K741K2.04M2.63M6.54M1.65M6.44M00015K000000000100K8.5M
Total Assets645.76M670.77M685.35M831.68M886.18M1.07B966.02M882.21M385.71M161.6M167M173.46M171.11M252.48M310.86M126.38M35.37M56.2M36.66M42.25M48.83M46.76M23.72M47.38M97.53M90.99M48.6M33.75M16.5M40.2M44.9M
Asset Turnover0.32x0.32x0.33x0.37x0.42x0.55x0.64x0.49x0.59x1.12x0.78x0.47x0.32x0.10x-----0.17x0.01x0.01x0.04x0.16x0.67x0.05x0.32x0.33x0.61x0.60x0.48x
Asset Growth %-31.95%-2.13%-17.59%-6.15%-17.03%10.56%9.5%128.72%138.69%-3.23%-3.73%1.38%-32.23%-18.78%145.97%257.34%-37.07%53.3%-13.25%-13.46%4.42%97.12%-49.93%-51.43%7.19%87.24%43.98%104.56%-58.96%-10.47%26.12%
Total Current Liabilities179.64M194.46M179.95M259.28M259.48M370.68M307.44M242.25M157.26M108.53M76.25M50.72M40.31M37.54M25.2M8.45M7.58M6.69M7.11M15.41M10.76M8M4.34M53.73M66.97M53.74M4.54M20.05M21.2M23.1M8.1M
Accounts Payable48.15M45.35M40.37M52.76M64.6M114.92M105.88M49.95M37.63M25.16M6.06M10.83M8.53M6.38M17.46M4.42M4.45M2.46M1.96M3.46M2.1M779K1.09M3.56M3.07M3.02M1.83M3.57M8.4M2.9M2M
Days Payables Outstanding156.32178.43100.07136.22186.09345.73294189.88251.83204.2564.39141.84151.9195.3414.12K16.06K16.24K1.54K----3.71K109.2137.2351.41144.85437.98828.65378.04182.5
Short-Term Debt000000050.13M34.24M22.83M31.3M14.74M15.39M12.97M00001.04M10K011K031.5M27.55M45.34M248K9.14M7.6M12.7M200K
Deferred Revenue (Current)0002.34M2.2M2.65M2.93M2.34M1.22M1.64M1.17M923K16.27M1.7M000006.34M06.27M013.65M9.48M1.88M1.04M0000
Other Current Liabilities131.49M149.1M139.58M185.23M35.64M45.6M28.79M16.59M72M5.16M5.8M4.28M2.25M10.24M3.16M1.78M0986.01K334K5.6M444K943K541K5.01M26.87M3.5M1.42M7.34M5.2M7.5M5.9M
Current Ratio3.48x3.34x3.31x2.80x2.66x2.37x2.86x3.53x2.40x1.41x1.92x2.83x3.60x5.84x11.34x14.08x4.37x8.37x2.27x1.41x3.68x4.58x2.99x0.27x0.71x0.77x5.41x0.60x0.30x0.97x2.58x
Quick Ratio2.46x2.33x2.39x1.80x1.77x1.74x2.25x3.21x2.04x1.13x1.65x2.46x3.26x5.28x10.49x14.08x4.37x8.37x2.27x1.35x3.64x4.58x2.99x0.22x0.60x0.71x4.79x0.43x0.25x0.91x2.41x
Cash Conversion Cycle705.28808.99506.8690.33602.3462.69322.32200.83240.91132.79209.51168.48145.6505.02---------38.14137.37537177.82205.09-588.74-97.42196.51
Total Non-Current Liabilities16.71M17.03M19.22M20.31M31.37M30.28M31.07M31.7M76.12M118.17M99.81M251.93M219.25M248.79M289.65M123.89M230.16M902K651K2.69M235K180K2.69M35.06M36.78M7.59M12.89M1.52M8.8M2.4M13.5M
Long-Term Debt5.58M6.08M00000046.11M99.83M85.16M230.12M211.46M237.03M233.98M00002.05M014K2M021.52M6.62M9.37M942K2M2.2M13.2M
Capital Lease Obligations13.42M6.08M7.72M8.74M10.02M8.58M9.15M9.44M0000000764K88K570K000000193K0141K0000
Deferred Tax Liabilities0000000001.74M08.17M000000000000000575K200K200K200K
Other Non-Current Liabilities11.12M4.87M11.5M9.06M8.21M7.65M6.21M3.75M10.52M1.15M710K8.51M7.79M11.76M55.67M123.13M230.07M332K651K642K235K166K687K015.07M973K3.38M06.6M0100K
Total Liabilities196.35M211.49M199.17M279.59M290.85M400.97M338.52M273.95M233.38M226.7M176.06M302.65M259.56M286.33M314.85M132.34M237.73M7.59M7.76M18.11M10.99M8.18M7.03M53.73M103.75M61.33M17.43M21.57M30M25.5M21.6M
Total Debt5.58M12.16M7.72M8.74M10.02M8.58M9.15M59.57M80.35M122.66M116.45M244.86M226.86M248.13M233.98M764K88K002.06M0176K2M31.5M49.26M51.95M9.76M10.08M9.6M14.9M13.4M
Net Debt-125.48M-122.7M-113.31M-190.51M-207.65M-210.88M-177.81M-585.01M-168.88M49.02M18.2M137.9M107.32M56.62M-26.26M-115.84M-31.35M-52.26M-11.24M-16.24M-36.8M-33.73M-8.99M29.4M24.97M21.83M7.74M8.47M8.8M9.3M8.6M
Debt / Equity0.01x0.03x0.02x0.02x0.02x0.01x0.01x0.10x0.53x----------0.09x-0.00x0.12x--1.75x0.31x0.83x-1.01x0.58x
Debt / EBITDA-0.16x----0.64x-------------------3.22x-----
Net Debt / EBITDA3.65x-----15.79x-------------------1.35x-----
Interest Coverage--5148.71x-11027.57x-6734.75x-6919.33x88.52x-5.67x-2.39x-12.09x-4.61x-3.07x-4.89x-2.20x-3.96x-8.44x-66894.00x-13158.00x-6.77x-9.39x-6.01x--11.16x---1.15x----0.43x-10.13x-
Total Equity449.41M459.28M486.18M552.1M595.33M667.1M627.5M608.26M152.33M-65.1M-9.06M-129.19M-88.45M-33.86M-4M-5.96M-202.37M48.6M28.9M24.15M37.84M38.58M16.69M-6.35M-6.21M29.67M31.17M12.18M-13.5M14.7M23.3M
Equity Growth %-40.05%-5.53%-11.94%-7.26%-10.76%6.31%3.16%299.31%333.99%-618.7%92.99%-46.06%-161.25%-747.04%32.96%97.05%-516.38%68.18%19.67%-36.17%-1.93%131.11%362.96%-2.16%-120.95%-4.82%155.88%190.23%-191.84%-36.91%-19.38%
Book Value per Share21.6122.1323.6627.0929.6833.1532.8735.5210.25-4.81-0.86-14.30-10.18-4.05-0.56-0.92-40.3822.9126.2051.5594.21190.94120.42-74.20-133.10141.75740.291624.78-1800.001985.683286.32
Total Shareholders' Equity449.41M459.28M486.18M552.1M595.33M667.1M627.5M608.26M152.33M-65.1M-9.06M-129.19M-88.45M-33.86M-4M-5.96M-202.37M48.6M28.9M24.15M37.84M38.58M16.69M-6.35M-6.21M29.67M31.17M12.18M-13.5M14.7M23.3M
Common Stock314.06M310.18M305.3M302.76M299M294.03M290.12M269.17M246.66M208.77M207.17M149.98M143.11M141.48M124.6M113.32M90.47M83.93M25.93M12.94M7.99M6.78M3.21M29.09M15.85M11.18M10.19M3.07M2.5M00
Retained Earnings-1.72B-1.71B-1.67B-1.59B-1.53B-1.42B-1.43B-1.41B-1.39B-1.27B-1.2B-1.12B-970.23M-913.87M-747.64M-568.46M-499.33M-271.3M-203.77M-185.19M-144.43M-119.71M-101M-105.66M-84.84M-41.57M-37.58M-46.03M-50.4M-21.9M-12.2M
Treasury Stock0-67.36M-65.33M-63.75M-61.77M-60.73M-51.08M-35.9M-10.41M-4.23M-1.51M-411K-217K-217K-217K-217K-217K-217K-217K-217K-217K-217K-217K00000000
Accumulated OCI000000000-816K0-754K-588K-400K0-200K-115K-2.57M-2.44M49.45M27.63M27.63M27.63M-977K-1.66M-1.5M-1.54M-520K-500K-5.4M-1M
Minority Interest0000000000000000000000000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Single product revenue erosion

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Asset Base Shrinkage Reflects Contraction

As reported in recent financial statements, Amarin's total assets have declined from $831.7 million in 2023Q4 to $645.8 million by 2026Q1, signaling a persistent contraction in the company's resource base as it navigates the erosion of its primary U.S. revenue stream and ongoing commercial restructuring.

The consistent reduction in total assets suggests that the company is consuming its capital base to fund operations rather than reinvesting for growth. This downward trajectory warrants close monitoring, as it may indicate a diminishing capacity to support long-term international expansion efforts.

Cash Runway Amid Operational Burn

Based on the latest quarterly data, Amarin maintains a cash position of $131.1 million as of 2026Q1, which, while providing a current ratio of 3.48, remains under pressure due to the company's ongoing inability to achieve consistent positive operating cash flow from its core pharmaceutical business.

While the current ratio appears superficially healthy, the lack of recurring revenue growth suggests that this liquidity buffer is finite. Investors should monitor the rate of cash depletion, as the current burn rate may necessitate further capital preservation measures or potential external financing.

Accumulated Deficit Erodes Equity Quality

According to historical balance sheet figures, Amarin's equity base has been significantly impaired by a persistent accumulated deficit of $1.7 billion, which underscores the long-term challenges the firm has faced in translating clinical success into sustainable, profitable operations for its shareholders.

The stagnation of retained earnings at this negative level suggests that the company has struggled to generate organic value, relying instead on external capital to sustain its business model. This structural weakness in the equity account highlights the high-risk nature of the current investment thesis.

Intangible Asset Risk and Impairment

As indicated by the company's reported figures, goodwill has steadily declined from $19.3 million in 2023Q4 to $12.7 million in 2026Q1, which may suggest ongoing management assessments of the carrying value of past acquisitions in light of the company's current commercial headwinds.

The gradual write-down of these intangible assets may imply that the strategic value of previous investments is being reassessed as the market environment for icosapent ethyl shifts. Further impairment charges could potentially impact the book value of equity, adding another layer of uncertainty to the balance sheet.

AMRN — Frequently Asked Questions

Quick answers to the most common questions about buying AMRN stock.

What are the total assets of Amarin Corporation plc (AMRN)?

As of 2025, Amarin Corporation plc (AMRN) had total assets of $670.8M including $649.9M in current assets.

How much debt does Amarin Corporation plc (AMRN) have?

Amarin Corporation plc (AMRN) carries total debt of $12.2M, offset by $302.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Amarin Corporation plc?

Amarin Corporation plc (AMRN) has total shareholders' equity (book value) of $459.3M ($22.13 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Amarin Corporation plc's current ratio and liquidity?

Amarin Corporation plc (AMRN) reported a current ratio of 3.34x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.